Cosecretion of peptide histidine methionine (PHM) and vasoactive intestinal peptide (VIP) in patients with VIP-producing tumors.

Fahrenkrug J, Pedersen JH

Peptides1 Sept 1986Cited by 15 (Europe PMC)

PMID3797338DOI10.1016/0196-9781(86)90084-7PepBankPUB-03797338

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Natural levels measured3

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

01HumanEndogenous levelObservational studyOther
In 39 patients with VIP-producing tumours, plasma VIP concentrations ranged from 29 to 2550 pmol/l.
In plain wordsIn 39 patients with VIP-producing tumours, the body's own VIP in blood ranged widely, from 29 to 2550 pmol/l.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicablePlasma VIP concentration in VIP-producing tumours
Study
n = 39
Outcome group
Endogenous peptide levels · Cancer
Measurements
Plasma VIP concentration
29 to 2550 pmol/l
patients with VIP-producing tumors
Source sentences
Summary
Plasma VIP concentrations ranged from 29 to 2550 pmol/l
1 context sentence(design, population, supporting numbers)
Summary · context
Regional specific antibodies and chromatography were used to analyze the concentration and molecular forms of vasoactive intestinal peptide (VIP) and peptide histidine methionine (PHM) in plasma from 39 patients with VIP-producing tumors.
This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0379733801
02HumanEndogenous levelObservational studyOther
In 39 patients with VIP-producing tumours, plasma C-terminal PHM values correlated closely with VIP concentrations.
In plain wordsIn 39 patients with VIP-producing tumours, blood PHM measured at one end of the molecule tracked the body's own VIP levels closely.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableCorrelation of C-terminal PHM with VIP
Study
n = 39
Outcome group
Endogenous peptide levels · Cancer
Source sentences
Summary
Plasma VIP concentrations ranged from 29 to 2550 pmol/l and the corresponding PHM immunoreactive values measured with C-terminally directed antibody were 42 to 2100 pmol/l which correlated closely with the VIP concentrations.
1 context sentence(design, population, supporting numbers)
Summary · context
Regional specific antibodies and chromatography were used to analyze the concentration and molecular forms of vasoactive intestinal peptide (VIP) and peptide histidine methionine (PHM) in plasma from 39 patients with VIP-producing tumors.
This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0379733802
03HumanEndogenous levelObservational studyOther
In 39 patients with VIP-producing tumours, N-terminal PHM concentrations were higher than C-terminal values and correlated poorly with VIP concentrations.
In plain wordsIn 39 patients with VIP-producing tumours, PHM measured at the other end of the molecule tracked the body's own VIP levels poorly.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableCorrelation of N-terminal PHM with VIP
Study
n = 39
Outcome group
Endogenous peptide levels · Cancer
Source sentences
Summary
N-terminal PHM concentrations were significantly higher than the C-terminal values ranging from 92 to 5850 pmol/l and correlated poorly with the corresponding VIP concentrations.
1 context sentence(design, population, supporting numbers)
Summary · context
Regional specific antibodies and chromatography were used to analyze the concentration and molecular forms of vasoactive intestinal peptide (VIP) and peptide histidine methionine (PHM) in plasma from 39 patients with VIP-producing tumors.
This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0379733803

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.